Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer

被引：0
|
作者：
Nicolai Mader
Christina Nguyen Ngoc
Bilge Kirkgöze
Justus Baumgarten
Daniel Groener
Konrad Klimek
Christian Happel
Nikolaos Tselis
Felix K. H. Chun
Frank Grünwald
Amir Sabet
机构：
[1] University Hospital Frankfurt,Department of Nuclear Medicine
[2] University Hospital Frankfurt,Department of Radiation Oncology
[3] University Hospital Frankfurt,Department of Urology
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2023年 / 50卷
关键词：
Prostate-specific membrane antigen (PSMA); [; Lu]Lu-PSMA; Radioligand therapy (RLT); Extended treatment; Metastatic castration-resistant prostate cancer (mCRPC);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1811 / 1821
页数：10
相关论文
共 50 条
  • [1] Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer
    Mader, Nicolai
    Ngoc, Christina Nguyen
    Kirkgoeze, Bilge
    Baumgarten, Justus
    Groener, Daniel
    Klimek, Konrad
    Happel, Christian
    Tselis, Nikolaos
    Chun, Felix K. H.
    Gruenwald, Frank
    Sabet, Amir
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (06) : 1811 - 1821
  • [2] Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer
    Houede, Nadine
    Hebert, Kevin
    LANCET ONCOLOGY, 2024, 25 (05): : 531 - 533
  • [3] Castration-resistant prostate cancer: [177Lu]Lu-PSMA-617 versus cabazitaxel Comment
    Todenhoefer, Tilman
    AKTUELLE UROLOGIE, 2023, 54 (04)
  • [4] Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy
    Ahmadzadehfar, Hojjat
    Schlolaut, Stephan
    Fimmers, Rolf
    Yordanova, Anna
    Hirzebruch, Stefan
    Schlenkhoff, Carl
    Gaertner, Florian C.
    Awang, Zool Hilmi
    Hauser, Stefan
    Essler, Markus
    ONCOTARGET, 2017, 8 (61) : 103108 - 103116
  • [5] Personalized dosimetry assessment of [177Lu]Lu-PSMA-617 radioligand therapy in the management of metastatic castration-resistant prostate cancer
    Kazemi-Jahromi, Mahmood
    Yazdani, Elmira
    Karamzade-Ziarati, Najme
    Asadi, Mahboobeh
    Sadeghi, Mahdi
    Geramifar, Parham
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2024, 100 (11) : 1551 - 1559
  • [6] Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Philipp E. Hartrampf
    Franz-Xaver Weinzierl
    Andreas K. Buck
    Steven P. Rowe
    Takahiro Higuchi
    Anna Katharina Seitz
    Hubert Kübler
    Andreas Schirbel
    Markus Essler
    Ralph A. Bundschuh
    Rudolf A. Werner
    European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49 : 3269 - 3276
  • [7] Lu-PSMA-617 for metastatic castration-resistant Prostate Cancer
    Lorenz, Judith
    AKTUELLE UROLOGIE, 2022, 53 (02) : 106 - 106
  • [8] Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
    Hartrampf, Philipp E.
    Weinzierl, Franz-Xaver
    Buck, Andreas K.
    Rowe, Steven P.
    Higuchi, Takahiro
    Seitz, Anna Katharina
    Kuebler, Hubert
    Schirbel, Andreas
    Essler, Markus
    Bundschuh, Ralph A.
    Werner, Rudolf A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (09) : 3269 - 3276
  • [9] [177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer
    Derlin, Thorsten
    Schmuck, Sebastian
    LANCET ONCOLOGY, 2018, 19 (08): : E372 - E372
  • [10] COST-EFFECTIVENESS OF [177LU]LU-PSMA-617 IN PROGRESSIVE PSMA-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Brockbank, J.
    Hancock, H.
    Khare, A.
    Joshi, P.
    Risson, V
    VALUE IN HEALTH, 2024, 27 (12) : S121 - S121
12345